Leukemia clinical trials in Tennessee
15 studies for Leukemia are looking for participants at sites in Tennessee.
Cities in Tennessee
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Baptist Clinical Research Institute, Memphis
- Tennessee Oncology, Nashville
- TriStar Centennial Medical Center, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07007312A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07751991Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Sarah Cannon Research Institute at TriStar Centennial Medical Center, Nashville
RecruitingPhase 3
Ages 18 to 71 · All sexes · Updated Oct 30, 2026 · NCT07504458Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- TriStar BMT, Nashville
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- East Tennessee Childrens Hospital, Knoxville
- St. Jude Children's Research Hospital, Memphis
- Vanderbilt University/Ingram Cancer Center, Nashville
RecruitingObservational study
All ages · All sexes · Updated Oct 20, 2026 · NCT00736749A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT04256317A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
- St. Jude Children's Research Hospital, Memphis
RecruitingPhase 1
Up to age 25 · All sexes · Updated Sep 15, 2026 · NCT06810583Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07284433Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Vanderbilt University, Ingram Cancer Center, Nashville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Baptist Clinical Research Institute, Memphis
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- TriStar Bone Marrow Transplant, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Memphis
- Massive Bio SYNERGY-AI site, Nashville
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- Sarah Cannon Research Institute, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT06501196Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- TriStar Bone Marrow Transplant, Nashville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 15, 2024 · NCT06034275From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.